Výsledky vyhledávání - "Mulder, Emma R."

89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding

Autor: van Brummelen, Emilie M J, Huisman, Marc C, de Wit-van der Veen, Linda J, Nayak, Tapan K, Stokkel, Marcel P M, Mulder, Emma R, Hoekstra, Otto S, Vugts, Danielle J, Van Dongen, Guus A M S, Verheul, Henk M, Evers, Stefan, Tessier, Jean J L, Saro, Jose, Schellens, Jan H M, Menke-van der Houven van Oordt, C Willemien, Sub Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology

Publikováno v: van Brummelen, E M J, Huisman, M C, de Wit-van der Veen, L J, Nayak, T K, Stokkel, M P M, Mulder, E R, Hoekstra, O S, Vugts, D J, Van Dongen, G A M S, Verheul, H M, Evers, S, Tessier, J J L, Saro, J, Schellens, J H M & Menke-van der Houven van Oordt, C W 2018, ' 89 Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors : CEA-mediated tumor accumulation and role of IL-2 receptor-binding ', Oncotarget, vol. 9, no. 37, pp. 24737-24749 . https://doi.org/10.18632/oncotarget.25343
Oncotarget, 9(37), 24737-24749. Impact Journals
Oncotarget, 9(37), 24737. Impact Journals LLC
Oncotarget

Cergutuzumab amunaleukin (CEA-IL2v) is an immunocytokine directed against carcinoembryonic antigen (CEA) containing an IL2v-moiety with abolished IL-2 receptor (IL-2R) a binding. We describe the biodistribution and tumor accumulation of 89Zr-labeled

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb90a7b96122887124900b30c3454982
https://doi.org/10.18632/oncotarget.25343

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání